- Research version
- v1.0
- As of
- 09/06/2026, 20:57 UTC
Research mandate
Can JPMorgan grow earnings if interest income falls and credit losses normalize?
Balanced
- Decisive variable
- Downside path
- Next decision check
- Date pending
- JPM current price
- USD 358.64-0.94%
The evidence supports a narrower conclusion; the original investment thesis remains unconfirmed. Evidence review: The cited evidence does not establish daily or weekly trend regimes, support zones, or peer-relative performance. The evidence supports the price-to-book ratio, EPS and book value, but does not support the stated ROE, operating margin, or the causal valuation conclusion.
Some supporting evidence was only partially verified. It cannot establish the original conclusion on its own. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The evidence supports lower-rate sensitivity and balance-sheet offsets, but does not adequately substantiate the cited 2025 Form 10-K conclusion or the asymmetric rate-downside claim.
Reassess the conclusion when subsequent company disclosures resolve the unverified assumptions. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The release supports higher loans and deposits and some rate offset, but the evidence does not fully establish revolving card and wholesale-loan effects or the broader earnings conclusion.
No invented probabilities: each path states what would reinforce or break the view.
Balanced
The evidence supports a narrower conclusion; the original investment thesis remains unconfirmed. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The release supports higher loans and deposits and some rate offset, but the evidence does not fully establish revolving card and wholesale-loan effects or the broader earnings conclusion.
Some supporting evidence was only partially verified. It cannot establish the original conclusion on its own. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The evidence supports lower-rate sensitivity and balance-sheet offsets, but does not adequately substantiate the cited 2025 Form 10-K conclusion or the asymmetric rate-downside claim.
If subsequent quarters show declining or stable charge-offs, no material reserve build and stable delinquency or nonaccrual trends across cards and wholesale portfolios, the projected credit-loss transmission would weaken.
Reassess the conclusion when subsequent company disclosures resolve the unverified assumptions. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The release supports higher loans and deposits and some rate offset, but the evidence does not fully establish revolving card and wholesale-loan effects or the broader earnings conclusion.
JUNE / CHART RESEARCH
Chart structure & the next move
Weekly context. Daily structure. Four-hour setup. Hourly confirmation.
Loading saved chart analysis…
Core claim audit
Each core claim connects the verified fact, unresolved countercase, and next checkpoint.
- Investor checkpoint
- If subsequent quarters show declining or stable charge-offs, no material reserve build and stable delinquency or nonaccrual trends across cards and wholesale portfolios, the projected credit-loss transmission would weaken.
- Investor checkpoint
- If a sustained credit deterioration materially reduces liquidity or capital buffers, or prompts constrained lending and capital distributions, this balance-sheet mitigation would no longer support earnings resilience.
Where the teams disagree
Compare the four independent team views and how each shaped the final call.
| Team | Independent view | Why it matters | Investor checkpoint |
|---|---|---|---|
 Market team · MayaAbstain | Only the findings that passed the evidence review are retained as established facts. Evidence review: The cited evidence does not establish daily or weekly trend regimes, support zones, or peer-relative performance. The evidence supports the price-to-book ratio, EPS and book value, but does not support the stated ROE, operating margin, or the causal valuation conclusion. | Some supporting evidence was only partially verified. It cannot establish the original conclusion on its own. | |
 Company team · EthanAbstain | Only the findings that passed the evidence review are retained as established facts. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The cited material supports the existence of a broad platform and some growth metrics, but does not establish that client activity can be redirected into recurring fee revenue as rates fall. | Some supporting evidence was only partially verified. It cannot establish the original conclusion on its own. | |
 Financial team · NoahAbstain | Only the findings that passed the evidence review are retained as established facts. Evidence review: The release supports higher loans and deposits and some rate offset, but the evidence does not fully establish revolving card and wholesale-loan effects or the broader earnings conclusion. The evidence supports higher revenue and expense figures, but does not demonstrate the claimed operating-leverage bridge after excluding significant items. | Some supporting evidence was only partially verified. It cannot establish the original conclusion on its own. | |
 Risk team · LiamAbstain | Only the findings that passed the evidence review are retained as established facts. Evidence review: The evidence supports $27.3 billion of expense and significant-item effects, but does not substantiate the detailed cost categories or the proposed early-warning conclusion. The earnings-release evidence supports $2.5 billion of provision expense, $2.4 billion of charge-offs and a $149 million reserve build, while the stated downside is appropriately framed as a risk rather than an observed deterioration. | Some supporting evidence was only partially verified. It cannot establish the original conclusion on its own. | If subsequent quarters show declining or stable charge-offs, no material reserve build and stable delinquency or nonaccrual trends across cards and wholesale portfolios, the projected credit-loss transmission would weaken. |
Market expectations and earnings hurdle
Separate market estimates embedded in the price from the operating proof the company still has to deliver.
- Forward revenue
- $207.5B
- Forward EPS
- $24.08
- Consensus price target
- $375
- High price target
- $420
Book-value and return bridge
Book value per share is tested across explicit price-to-book assumptions; profitability and asset quality determine whether each multiple is defensible.
- Price / book
- 1.4x
Book value per share $133.01 × 1.42x P/B · Normalized ROE 15.1%, cost of equity 11.5%, perpetual growth 3%
- Price / book
- 2x
Book value per share $133.01 × 1.97x P/B · Normalized ROE 16.8%, cost of equity 10.5%, perpetual growth 4%
- Price / book
- 2.8x
Book value per share $133.01 × 2.82x P/B · Normalized ROE 17.7%, cost of equity 9.5%, perpetual growth 5%
The available evidence does not establish the assumptions needed for a reliable valuation comparison. Evidence review: The evidence supports the price-to-book ratio, EPS and book value, but does not support the stated ROE, operating margin, or the causal valuation conclusion.
- 01Consensus estimates
- Forward revenue $207.5B · Forward EPS $24.08 · Consensus price target $375
- 02Recent operating results
- Operating margin 48.1% · Free cash flow $153.7B · Operating cash flow $153.7B
- 03Proof due at the next filing
- If subsequent quarters show declining or stable charge-offs, no material reserve build and stable delinquency or nonaccrual trends across cards and wholesale portfolios, the projected credit-loss transmission would weaken.
Investor Q&A
3 questions answered by the evidence in this research.
What is the report’s answer to the research question?
The evidence supports a narrower conclusion; the original investment thesis remains unconfirmed. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The release supports higher loans and deposits and some rate offset, but the evidence does not fully establish revolving card and wholesale-loan effects or the broader earnings conclusion. Countercase: Some supporting evidence was only partially verified. It cannot establish the original conclusion on its own. Evidence review: The supplied release evidence supports stronger reported revenue, Markets activity and significant items, but the attached citations do not adequately establish broad noninterest growth across CCB, CIB and AWM or durable earnings resilience. The evidence supports lower-rate sensitivity and balance-sheet offsets, but does not adequately substantiate the cited 2025 Form 10-K conclusion or the asymmetric rate-downside claim.
How crowded is the positive analyst view, and what does that imply for surprise risk?
52% of 23 tracked recommendations are buys (12 buy, 11 hold, 0 sell). That crowding raises the upside-surprise hurdle and makes the stock more sensitive to even a modest estimate cut; consensus support is therefore expectation risk, not an independent buy signal.
Which hard evidence makes the risk buffer case decision-relevant now?
At fiscal 2Q26, JPMorgan reported $1.5 trillion of cash and marketable securities and $590 billion of total loss-absorbing capacity. This liquidity and capital buffer reduces the risk that ordinary credit normalization or rate shocks force a destabilizing balance-sheet response, although it does not prevent earnings volatility. Decision checkpoint: If a sustained credit deterioration materially reduces liquidity or capital buffers, or prompts constrained lending and capital distributions, this balance-sheet mitigation would no longer support earnings resilience.
Show 27 sources
Sources & evidence register
Sources are grouped by the report chapter they support, with publisher, publication or observation date, and evidence class. Filings show their filing date; market data shows its observation date.
Decision summary
Priority evidence supporting the direct answer and headline judgment
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Bureau of Labor Statisticsbls allowlistCheck date
- risk_policy
memo:risk_policy
memoCheck date - financial
memo:financial
memoCheck date - risk
memo:risk
memoCheck date - valuation
memo:valuation
memoCheck date - risk
challenge:risk
blind challengeCheck date
Business & earnings
Evidence used to assess the business, growth, profitability, and issuer-specific risks
- Stocksembly market data
Company fundamentals
Market evidenceCheck date - U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC XBRLCheck date
- U.S. Bureau of Labor Statisticsbls allowlistCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- company
memo:company
memoCheck date - company_competition
memo:company_competition
memoCheck date - company_product
memo:company_product
memoCheck date
Valuation & comparison
Market, technical, rates, peer, and relative-valuation evidence
- Stocksembly market data
Company fundamentals
Market evidenceCheck date - Stocksembly market data
Market evidence dataset
Market evidenceCheck date - Stocksembly market data
Market evidence dataset
Market evidenceCheck date - Stocksembly market data
Current market snapshot
Market evidenceCheck date - Stocksembly market data
Market evidence dataset
Market evidenceCheck date - Stocksembly market data
Market evidence dataset
Market evidenceCheck date - benchmark
memo:benchmark
memoCheck date - market
memo:market
memoCheck date - market_news
memo:market_news
memoCheck date - market
challenge:market
blind challengeCheck date
Debate & final judgment
Audited evidence revisited during challenge, recheck, and chair synthesis
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date
- U.S. Securities and Exchange CommissionSEC filingCheck date